The Effect of Glioblastoma PSMA Expression Following Tumour VEGF Blockade From Bevacizumab (NCT07052877) | Clinical Trial Compass
RecruitingNot Applicable
The Effect of Glioblastoma PSMA Expression Following Tumour VEGF Blockade From Bevacizumab
Australia20 participantsStarted 2025-12-11
Plain-language summary
This trial is a single arm study for patients receiving bevacizumab for IDH-wildtype glioblastoma. Patients receiving bevacizumab (an anti-VEGF therapy) will receive PSMA scans to investigate the role of PSMA expression in glioblastoma and its relationship to VEGF expression.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* \> 18 year of age
* ECOG 0-2
* Able to provide informed consent for the study
* Minimum of 1 month from completion of radiotherapy with clinical or radiography evidence suggesting residual tumour
* Confirmed glioblastoma IDH1/2 wildtype (WHO2021)
* For bevacizumab treatment as per treating physician
* Able to comply with trial requirements
Exclusion Criteria:
* No major organ impairment that would likely lead to unacceptable toxicities- eg significant cardiac, hepatic, renal or haematologic dysfunction (based on clinician assessment)
* Any contraindication to bevacizumab, MRI gadolinium contrast or 68Ga-PSMA-617 radioisotope
* Any implant, foreign body, 3T MRI incompatible device or other contraindication to MRI imaging
* Does not fulfill PBS requirements for bevacizumab
* Women lactating, pregnant or of child baring potential who are not willing to avoid pregnancy during the study
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Changes in PSMA PET metabolic tumour volume (MTV) before and after bevacizumab administration.
Timeframe: Prior to first administration of bevacizumab to 6 weeks after.